

Supplementary Table S1. Clinical manifestations of SLE included in the present study.

Clinical manifestation	Items included
Constitutional symptoms	Fever (according to SLEDAI), and weight loss, lymphadenopathy and splenomegaly (according to BILAG)
Cutaneous	Inflammatory skin eruption and alopecia (according to SLEDAI),
Musculoskeletal	Arthritis and myositis (according to SLEDAI)
Respiratory	Pleurisy, pulmonary haemorrhage/vasculitis, interstitial alveolitis/pneumonitis, shrinking lung syndrome (according to SLEDAI and BILAG),
Cardiac	Pericarditis, myocarditis, endocarditis, valvular dysfunction (according to SLEDAI and BILAG)
Renal	Nephritis and thrombotic microangiopathy
Neuropsychiatric	Psychosis, seizure disorder, organic brain syndrome, myelopathy, neuropathies, cognitive dysfunction, lupus headache (according to SLEDAI and BILAG)
Ophthalmological	Ophthalmic manifestatos (according to SLEDAI and BILAG)
Haematological	Leukopenia, lymphopenia, thrombocytopenia and haemolytic anaemia (according to SLEDAI and BILAG)
Gastrointestinal	Abdominal serositis, enteropathy and lupus hepatitis (according to BILAG)

Supplementary Table S2. Distribution of the different aPL across the SLE cohort.

		SLE no aPL n=2286	SLE APS n=555	SLE aPL n=817	Total n=3658
IgG aCL	Negative	2013	168	350	2531
	Positive	0	379	454	833
	Missing	273	8	13	294
IgM aCL	Negative	2019	263	407	2689
	Positive	0	281	396	677
	Missing	267	11	14	292
IgG aB2GP I	Negative	1268	215	391	1874
	Positive	0	147	146	293
	Missing	1018	193	280	1491
IgM aB2GP I	Negative	1269	232	371	1872
	Positive	0	132	168	300
	Missing	1017	191	278	1486
LA	Negative	1528	151	340	2019
	Positive	0	323	314	637
	Missing	758	81	163	1002

Supplementary Table S3. Association (OR and 95% CI) between the different aPL and SLE and APS manifestations.

		aCL	aB2GPI	LA
SLE manifestations	n (%) n=2398			
Constitutional symptoms	442 (18.4)	1.10 (0.92-1.31) <i>p</i> =0.299	1.02 (0.80-1.32) <i>p</i> =0.857	1.19 (0.95-1.48) <i>p</i> =0.136
Cutaneous manifestations	1729 (72.1)	0.81 (0.70-0.95) <i>p</i> =0.011	0.78 (0.63-0.97) <i>p</i> =0.027	0.79 (0.65-0.97) <i>p</i> =0.021
Joint symptoms	1854 (77.3)	0.99 (0.83-1.17) <i>p</i> =0.870	0.93 (0.74-1.18) <i>p</i> =0.563	0.72 (0.58-0.88) <i>p</i> =0.001
Respiratory	620 (25.9)	1.16 (0.99-1.37) <i>p</i> =0.063	0.97 (0.77-1.22) <i>p</i> =0.811	1.17 (0.96-1.43) <i>p</i> =0.113
Cardiac	590 (24.6)	1.17 (0.97-1.40) <i>p</i> =0.092	0.98 (0.76-1.28) <i>p</i> =0.903	1.23 (0.99-1.54) <i>p</i> =0.058
Renal	956 (39.9)	1.00 (0.86-1.15) <i>p</i> =0.970	0.92 (0.75-1.13) <i>p</i> =0.433	1.21 (1.01-1.44) <i>p</i> =0.042
Neuropsychiatric	433 (18.1)	1.45 (1.21-1.74) <i>p</i> <0.001	1.15 (0.89-1.49) <i>p</i> =0.280	1.56 (1.26-1.94) <i>p</i> <0.001
Ophthalmological	113 (4.9)	1.77 (1.28-2.45) <i>p</i> =0.001	1.57 (1.02-2.41) <i>p</i> =0.039	1.73 (1.20-2.50) <i>p</i> =0.004
Haematologic	1905 (79.4)	1.20 (1.01-1.43) <i>p</i> =0.042	0.98 (0.77-1.24) <i>p</i> =0.848	1.37 (1.08-1.73) <i>p</i> =0.008
Gastrointestinal	116 (4.8)	1.29 (0.93-1.79) <i>p</i> =0.132	1.64 (1.08-2.48) <i>p</i> =0.019	1.22 (0.82-1.82) <i>p</i> =0.334
Non criteria APS manifestations				
Raynaud phenomenon	792 (34.1)	0.97 (0.83-1.13) <i>p</i> =0.690	0.97 (0.78-1.20) <i>p</i> =0.792	0.94 (0.78-1.14) <i>p</i> =0.527
Skin ulcers	77 (3.3)	1.39 (0.92-2.08) <i>p</i> =0.116	1.07 (0.59-1.93) <i>p</i> =0.826	1.36 (0.84-2.21) <i>p</i> =0.217
Thrombocytopenia	596 (25.9)	1.79 (1.52-2.11) <i>p</i> <0.001	1.41 (1.12-1.77) <i>p</i> =0.003	2.29 (1.88-2.79) <i>p</i> <0.001
Haemolytic anaemia	225 (9.6)	1.68 (1.30-2.56) <i>p</i> <0.001	1.46 (0.91-2.28) <i>p</i> =0.021	2.08 (1.58-2.74) <i>p</i> <0.001
Evans syndrome	106 (4.6)	1.83 (1.30-2.56) <i>p</i> <0.001	1.44 (0.91-2.28) <i>p</i> =0.117	2.65 (1.80-3.88) <i>p</i> <0.001
Valvular dysfunction	82 (3.6)	1.33 (0.91-1.94) <i>p</i> =0.134	1.34 (0.81-2.21) <i>p</i> =0.250	1.76 (1.14-2.72) <i>p</i> =0.011
Libman Sacks endocarditis	30 (1.3)	2.82 (1.44-5.5) <i>p</i> =0.002	1.53 (0.63-3.72) <i>p</i> =0.343	7.57 (3.59-16) <i>p</i> <0.001
Headache	143 (6.1)	1.42 (1.06-1.80) <i>p</i> =0.018	0.98 (0.64-1.51) <i>p</i> =0.935	1.11 (0.77-1.60) <i>p</i> =0.562
Cognitive impairment	81 (3.4)	1.77 (1.19-2.60) <i>p</i> =0.005	1.67 (1.01-2.78) <i>p</i> =0.047	1.84 (1.17-2.90) <i>p</i> =0.009
Thrombotic microangiopathy	13 (0.6)	0.48 (0.14-1.60) <i>p</i> =0.242	0.93 (0.21-4.06) <i>p</i> =0.922	2.06 (0.67-6.31) <i>p</i> =0.208
APS manifestations				
Arterial thrombosis	159 (6.7)	5.74 (4.13-7.97) <i>p</i> <0.001	4.87 (3.52-6.74) <i>p</i> <0.001	4.45 (3.16-6.28) <i>p</i> <0.001
Venous thrombosis	297 (12.5)	3.95 (3.14-4.97) <i>p</i> <0.001	2.34 (1.77-3.08) <i>p</i> <0.001	4.86 (3.77-6.26) <i>p</i> <0.001
Small-vessel thrombosis	123 (5.3)	5.06 (3.50-7.32) <i>p</i> <0.001	3.03 (2.04-4.49) <i>p</i> <0.001	4.75 (3.24-6.95) <i>p</i> <0.001
Fetal death	126 (5.7)	1.81 (1.31-2.49) <i>p</i> <0.001	1.85 (1.24-2.76) <i>p</i> =0.003	1.73 (1.20-2.50) <i>p</i> =0.003
Preterm birth	50 (2.3)	1.68 (1.04-2.72) <i>p</i> =0.035	0.56 (0.22-1.40) <i>p</i> =0.217	1.84 (1.06-3.19) <i>p</i> =0.031
≥3 pregnancy losses	50 (2.3)	4.47 (2.58-7.74) <i>p</i> <0.001	4.48 (2.59-7.75) <i>p</i> <0.001	4.06 (2.25-7.30) <i>p</i> <0.001

OR: odds ratio; CI: confidence interval; aPL: antiphospholipid antibodies; APS: antiphospholipid syndrome; SLE: systemic lupus erythematosus; aCL: anticardiolipin antibodies; aB2GPI: antiB2 glycoprotein I antibodies; LA: lupus anticoagulant.

Supplementary Table S4. Association (OR and 95% CI) between aPL isotypes and SLE and APS manifestations.

		IgG aCL	IgM aCL	IgG aB2GPI	IgM aB2GPI
SLE manifestations					
	n(%) n=2398				
Constitutional symptoms	442 (18.4)	1.10 (0.91-1.34) <i>p</i> =0.335	1.04 (0.84-1.28) <i>p</i> =0.723	1.32 (0.97-1.80) <i>p</i> =0.075	1.17 (0.85-1.60) <i>p</i> =0.330
Cutaneous manifestations	1729 (72.1)	0.80 (0.68-0.96) <i>p</i> =0.013	0.68 (0.57-0.82) <i>P</i> <0.001	0.86 (0.66-1.13) <i>p</i> =0.276	0.74 (0.57-0.96) <i>p</i> =0.022
Joint symptoms	1854 (77.3)	0.88 (0.74-1.06) <i>p</i> =0.188	1.05 (0.86-1.28) <i>p</i> =0.647	0.75 (0.57-0.99) <i>p</i> =0.042	1.05 (0.78-1.41) <i>p</i> =0.741
Respiratory	620 (25.9)	1.20 (1.01-1.43) <i>p</i> =0.040	0.98 (0.81-1.19) <i>p</i> =0.861	1.03 (0.77-1.37) <i>p</i> =0.835	1.05 (0.79-1.39) <i>p</i> =0.733
Cardiac	590 (24.6)	1.26 (1.04-1.54) <i>p</i> =0.019	1.15 (0.93-1.43) <i>p</i> =0.186	1.38 (1.01-1.88) <i>p</i> =0.046	1.19 (0.87-1.64) <i>p</i> =0.281
Renal	956 (39.9)	1.08 (0.92-1.26) <i>p</i> =0.374	0.92 (0.77-1.09) <i>p</i> =0.346	1.04 (0.81-1.34) <i>p</i> =0.733	0.92(0.71-1.18) <i>p</i> =0.518
Neuropsychiatric	433 (18.1)	1.37 (1.13-1.67) <i>p</i> =0.002	1.39 (1.13-1.72) <i>p</i> =0.002	1.36 (1.00-1.85) <i>p</i> =0.051	1.11 (0.80-1.52) <i>p</i> =0.535
Ophthalmological	113 (4.9)	1.46 (1.02-2.07) <i>p</i> =0.037	1.37 (0.94-2.00) <i>p</i> =0.104	2.11 (1.27-3.51) <i>p</i> =0.004	1.47 (0.84-2.57) <i>p</i> =0.174
Haematologic	1905 (79.4)	1.22 (1.00-1.49) <i>p</i> =0.049	1.07 (0.87-1.32) <i>p</i> =0.513	0.97 (0.72-1.30) <i>p</i> =0.820	1.21 (0.89-1.65) <i>p</i> =0.214
Gastrointestinal	116 (4.8)	1.43 (1.01-2.03) <i>p</i> =0.044	0.96 (0.64-1.44) <i>p</i> =0.841	1.87 (1.15-3.05) <i>p</i> =0.012	1.71 (1.04-2.81) <i>p</i> =0.035
Non criteria APS manifestations					
Raynaud phenomenon	792 (34.1)	0.98 (0.83-1.15) <i>p</i> =0.780	0.97 (0.81-1.16) <i>p</i> =0.710	1 (0.77-1.31) <i>p</i> =0.982	0.95 (0.73-1.24) <i>p</i> =0.720
Skin ulcers	77 (3.3)	1.23 (0.79-1.92) <i>p</i> =0.366	1.46 (0.92-2.30) <i>p</i> =0.105	1.30 (0.65-2.60) <i>p</i> =0.454	0.83 (0.37-1.85) <i>p</i> =0.649
Thrombocytopenia	596 (25.9)	1.76 (1.48-2.11) <i>p</i> <0.001	1.75 (1.45-2.12) <i>p</i> <0.001	1.59 (1.2-2.1) <i>p</i> =0.001	1.69 (1.29-2.23) <i>p</i> <0.001
Haemolytic anaemia	225 (9.6)	1.61 (1.24-2.07) <i>p</i> <0.001	1.75 (1.34-2.28) <i>p</i> <0.001	1.83 (1.24-2.71) <i>p</i> =0.002	2.01 (1.37-2.94) <i>p</i> <0.001
Evans syndrome	106 (4.6)	1.81 (1.26-2.60) <i>p</i> =0.001	2.20 (1.53-3.19) <i>p</i> <0.001	1.50 (0.85-2.67) <i>p</i> =0.166	1.73 (1-2.99) <i>p</i> =0.051
Valvular dysfunction	82 (3.6)	1.66 (1.12-2.46) <i>p</i> =0.01	1.24 (0.80-19.3) <i>p</i> =0.338	2.29 (1.28-4.11) <i>p</i> =0.005	2.08 (1.15-3.78) <i>p</i> =0.016
Libman Sacks endocarditis	30 (1.3)	3.94 (1.99-7.79) <i>p</i> <0.001	1.69 (0.80-3.55) <i>p</i> =0.167	3.56 (1.31-9.71) <i>p</i> =0.013	1.99 (0.64-6.14) <i>p</i> =0.232
Headache	143 (6.1)	1.18 (0.86-1.62) <i>p</i> =0.297	1.39 (1-1.93) <i>p</i> =0.047	1.08 (0.64-1.84) <i>p</i> =0.763	0.92 (0.53-1.61) <i>p</i> =0.784
Cognitive impairment	81 (3.4)	1.81 (1.19-2.74) <i>p</i> =0.005	1.76 (1.14-2.73) <i>p</i> =0.011	1.90 (1.05-3.42) <i>p</i> =0.033	1.21 (0.63-2.34) <i>p</i> =0.568
Thrombotic microangiopathy	13 (0.6)	0.44 (0.1-1.96) <i>p</i> =0.283	0.57 (0.13-2.53) <i>p</i> =0.464	1.88 (0.39-9.1) <i>p</i> =0.432	0.79 (0.1-6.3) <i>p</i> =0.823
APS manifestations					
Arterial thrombosis	159 (6.7)	7.28 (5.21- 0.16) <i>p</i> <0.001	2.43 (1.75-3.37) <i>p</i> <0.001	6.46 (4.42-9.46) <i>p</i> <0.001	3.48 (2.34-5.18) <i>p</i> <0.001
Venous thrombosis	297 (12.5)	3.99 (3.16-5.03) <i>p</i> <0.001	2.38 (1.86-3.04) <i>p</i> <0.001	3.16 (2.27-4.39) <i>p</i> <0.001	1.79 (1.25-2.57) <i>p</i> =0.001
Small-vessel thrombosis	123 (5.3)	4 (2.80-5.70) <i>p</i> <0.001	4.02 (2.81-5.75) <i>p</i> <0.001	3.64 (2.30-5.76) <i>p</i> <0.001	2.65 (1.64-4.29) <i>p</i> <0.001
Fetal death	126 (5.7)	1.89 (1.35-2.64) <i>p</i> <0.001	1.65 (1.16-2.36) <i>p</i> =0.006	1.76 (1.08-2.86) <i>p</i> =0.024	2.21(1.39-3.50) <i>p</i> =0.001
Preterm birth	50 (2.3)	1.7 (1.03-2.82) <i>p</i> =0.038	1.57 (0.92-2.68) <i>p</i> =0.098	0.78 (0.30-1.99) <i>p</i> =0.599	0.78 (0.30-1.98) <i>p</i> =0.597
>3 pregnancy losses	50 (2.3)	3.83 (2.24-6.55) <i>p</i> <0.001	3.14 (1.84-5.30) <i>p</i> <0.001	5.15 (2.65-9.99) <i>p</i> <0.001	4.59 (2.35-8.97) <i>p</i> <0.001

OR: odds ratio; CI: confidence interval; aPL: antiphospholipid antibodies; APS: antiphospholipid syndrome; SLE: systemic lupus erythematosus; aCL: anticardiolipin antibodies; aB2GPI: antiB2 glycoprotein I antibodies.

Supplementary Table S5. Association (OR and 95% CI) between the number of positive antibodies and SLE and APS manifestations.

		1+ aPL	2 + aPL	3 + aPL
SLE manifestations				
	n(%) n=2398			
Constitutional symptoms	442 (18.4)	1.04 (0.85-1.28) <i>p</i> =0.694	1.03 (0.80-1.34) <i>p</i> =0.800	1.25 (0.87-1.81) <i>p</i> =0.229
Cutaneous manifestations	1729 (72.1)	0.90 (0.75-1.09) <i>p</i> =0.273	0.77 (0.62-0.96) <i>p</i> =0.021	0.71 (0.51-0.98) <i>p</i> =0.038
Joint symptoms	1854 (77.3)	0.95 (0.78-1.16) <i>p</i> =0.601	0.87 (0.69-1.11) <i>p</i> =0.264	0.83 (0.58-1.17) <i>p</i> =0.286
Respiratory	620 (25.9)	1.06 (0.88-1.28) <i>p</i> =0.552	1.28 (1.03-1.61) <i>p</i> =0.029	1.09 (0.77-1.55) <i>p</i> =0.613
Cardiac	590 (24.6)	1.03 (0.83-1.28) <i>p</i> =0.777	1.44 (1.13-1.84) <i>p</i> =0.004	1.05 (0.71-1.56) <i>p</i> =0.814
Renal	956 (39.9)	1.09 (0.92-1.29) <i>p</i> =0.315	1.13 (0.92-1.39) <i>p</i> =0.262	1.04 (0.76-1.42) <i>p</i> =0.824
Neuropsychiatric	433 (18.1)	1.19 (0.95-1.48) <i>p</i> =0.129	1.71 (1.33-2.19) <i>p</i> <0.001	1.68 (1.16-2.42) <i>p</i> =0.006
Ophthalmological	113 (4.9)	1.44 (0.96-2.16) <i>p</i> =0.076	1.79 (1.13-2.62) <i>p</i> =0.013	3.05 (1.76-5.28) <i>p</i> <0.001
Haematologic	1905 (79.4)	1.12 (0.91-1.37) <i>p</i> =0.273	1.29 (1-1.67) <i>p</i> =0.054	1.38 (0.96-2.03) <i>p</i> =0.114
Gastrointestinal	116 (4.8)	1.01 (0.67-1.54) <i>p</i> =0.948	1.35 (0.85-2.14) <i>p</i> =0.201	2.03 (1.13-3.63) <i>p</i> =0.018
Non criteria APS manifestations				
Raynaud phenomenon	792 (34.1)	0.96 (0.85-1.15) <i>p</i> =0.669	0.99 (0.80-1.23) <i>p</i> =0.936	1.02 (0.74-1.42) <i>p</i> =0.884
Skin ulcers	77 (3.3)	1.44 (0.90-2.32) <i>p</i> =0.129	1.63 (0.94-2.84) <i>p</i> =0.083	1.19 (0.47-3.01) <i>p</i> =0.714
Thrombocytopenia	596 (25.9)	1.47 (1.21-1.79) <i>p</i> <0.001	2.21 (1.76-2.78) <i>p</i> <0.001	2.75 (1.98-3.80) <i>p</i> <0.001
Haemolytic anaemia	225 (9.6)	1.43 (1.07-1.92) <i>p</i> =0.017	2.20 (1.61-3.01) <i>p</i> <0.001	2.31 (1.47-3.64) <i>p</i> <0.001
Evans syndrome	106 (4.6)	1.51 (0.99-2.31) <i>p</i> =0.058	2.76 (1.79-4.25) <i>p</i> <0.001	2.48 (1.31-4.69) <i>p</i> =0.005
Valvular dysfunction	82 (3.6)	0.83 (0.5-1.4) <i>p</i> =0.489	2.21 (1.40-3.47) <i>p</i> =0.001	1.32 (0.60-2.91) <i>p</i> =0.497
Libman Sacks endocarditis	30 (1.3)	2.11 (0.8-5.57) <i>p</i> =0.130	6.89 (3-15.82) <i>p</i> <0.001	6.66 (2.25-19.71) <i>p</i> =0.001
Headache	143 (6.1)	1.33 (0.95-1.86) <i>p</i> =0.099	1.11 (0.72-1.72) <i>p</i> =0.641	1.57 (0.88-2.79) <i>p</i> =0.126
Cognitive impairment	81 (3.4)	1.3 (0.79-2.16) <i>p</i> =0.304	1.95 (1.14-3.33) <i>p</i> =0.015	2.93 (1.5-5.74) <i>p</i> =0.002
Thrombotic microangiopathy	13 (0.6)	1.42 (0.49-4.09) <i>p</i> =0.520	0.47 (0.06-3.66) <i>p</i> =0.472	1.23 (0.16-9.61) <i>p</i> =0.841
APS manifestations				
Arterial thrombosis	159 (6.7)	4.45 (2.86-6.92) <i>p</i> <0.001	9.23 (5.97-14.27) <i>p</i> <0.001	15.63 (9.5-25.73) <i>p</i> <0.001
Venous thrombosis	297 (12.5)	3.95 (2.96-5.28) <i>p</i> <0.001	5.9 (4.32-8.04) <i>p</i> <0.001	9.14 (6.21-13.47) <i>p</i> <0.001
Small-vessel thrombosis	123 (5.3)	3.69 (2.23-6.1) <i>p</i> <0.001	10.05 (6.28-16.08) <i>p</i> <0.001	9.51 (5.21-17.35) <i>p</i> <0.001
Fetal death	126 (5.7)	1.33 (0.88-2) <i>p</i> =0.175	2.46 (1.64-3.71) <i>p</i> <0.001	2.44 (1.35-4.41) <i>p</i> =0.003
Preterm birth	50 (2.3)	1.25 (0.68-2.30) <i>p</i> =0.464	2.14 (1.16-3.94) <i>p</i> =0.014	1.09 (0.33-3.57) <i>p</i> =0.89
>3 pregnancy losses	50 (2.3)	4.72 (2.26-9.85) <i>p</i> <0.001	7.15 (3.36-15.24) <i>p</i> <0.001	12.85 (5.58-29.66) <i>p</i> <0.001

OR: odds ratio; CI: confidence interval; aPL: antiphospholipid antibodies; APS: antiphospholipid syndrome; SLE: systemic lupus erythematosus.